Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation

Bulletin of Experimental Biology and Medicine

Volumn 157, Issue 1, 2014, Pages 52-55

  Kolik, L G ^a   Nadorova, A V ^a   Kozlovskaya, M M ^a  

^a INSTITUTE OF PHARMACOLOGY   (Russian Federation)

Author keywords

Alcohol withdrawal; Allodynia; Anxiety; Rats; Selank

Indexed keywords

ANXIOLYTIC AGENT; SELANK; UNCLASSIFIED DRUG; ALCOHOL; OLIGOPEPTIDE; TP 7;

ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; DRINKING BEHAVIOR; DRUG EFFICACY; ELEVATED PLUS MAZE TEST; MALE; MOTIVATION; NONHUMAN; RAT; SOCIAL INTERACTION TEST; ALCOHOLISM; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DRUG EFFECTS; HYPERALGESIA; INTRAPERITONEAL DRUG ADMINISTRATION; MAZE TEST; OUTBRED STRAIN; PATHOPHYSIOLOGY; PREVENTION AND CONTROL; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

ALCOHOLISM; ANIMALS; ANIMALS, OUTBRED STRAINS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; ETHANOL; HYPERALGESIA; INJECTIONS, INTRAPERITONEAL; MALE; MAZE LEARNING; OLIGOPEPTIDES; RATS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 84904313775     PISSN: 00074888     EISSN: 15738221     Source Type: Journal    
DOI: 10.1007/s10517-014-2490-4     Document Type: Article

References (14)

1. N. V. Kossh, V. K. Meshavkin, O. Yu. Sokolov, et al., Vestn. Ross. Akad. Med. Nauk, No. 3, 24-33 (2007).
2. A. V. Nadorova, M. M. Kozlovskaja, and S. B. Seredenin, Bull. Exp. Biol. Med., 148, No. 4, 609-611 (2009).
3. Narcology: National Guidance [in Russian], Eds. N. N. Ivanets, et al., Moscow (2008), pp. 199-227.
4. L. A. Andreeva, L. Yu. Alfeeva, I. A. Grivennikov, et al., Patent of RF No. 2155065. Anxiolytic Drug and Pharmaceutical Composition of Anxiolytic Effect, Byul. Izobr., No. 24, 236 (2000).
5. T. P. Semenova, I. I. Kozlovskii, N. M. Zakharova, and M. M. Kozlovskaya, Eksp. Klin. Farmakol., 73, No.8, 2-5, (2010).
6. E. S. Teleshova, V. K. Bochkarev, T. S. Syunyakov, et al., Psikhiatriya, No.4, 26-35 (2010).
7. T. Jukić, B. Rojc, D. Boben-Bardutzky, et al., Coll Antropol., 35, No. 4, 1225-1230 (2011).
8. R. Malcolm, H. Myrick, J. Roberts, et al., J. Gen. Intern. Med., 17, No. 5, 349-355 (2002).
9. D. H. Overstreet, D. J. Knapp, S. S. Moy, and G. R. Breese, Psychopharmacology, 167, No. 4, 344-352 (2003).
10. S. Pellow, P. Chopin, S. E. File, and M. Briley, J. Neurosci. Methods, 14, 149-167 (1985).
11. J. A. Shumilla, T. Liron, D. Mochly-Rosen, et al., J. Pain, 6, No. 8, 535-549 (2005).
12. V. B. Solov'ev, M. T. Gengin, T. N. Sollertinskaia, et al., Zh. Evol. Biokhim. Fiziol., 48, No. 3, 254-257 (2012).
13. A. Urayama, K. King, F. S. Gaskin, et al., Peptides, 27, No. 9, 2201-2206 (2006).
14. A. N. Vernigora, Zh. S. Bardinova, V. A. Smetanin, and M. T. Gengin, Ukr. Biokhim. Zh., 76, No. 3, 68-73 (2004).